scholarly journals Effects of U83836E on nerve functions, hyperalgesia and oxidative stress in experimental diabetic neuropathy

Life Sciences ◽  
2006 ◽  
Vol 79 (8) ◽  
pp. 777-783 ◽  
Author(s):  
Sufyan G. Sayyed ◽  
Ashutosh Kumar ◽  
Shyam S. Sharma
Keyword(s):  
Oxidative Stress ◽  
Diabetic Neuropathy ◽  
Experimental Diabetic Neuropathy ◽  
And Oxidative Stress

Alpha-lipoic acid and coenzyme Q10 combination ameliorates experimental diabetic neuropathy by modulating oxidative stress and apoptosis

Life Sciences ◽  
2019 ◽  
Vol 216 ◽  
pp. 101-110 ◽  
Author(s):  
Nasrin Sadeghiyan Galeshkalami ◽  
Mohammad Abdollahi ◽  
Rezvan Najafi ◽  
Maryam Baeeri ◽  
Akram Jamshidzade ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Diabetic Neuropathy ◽  
Lipoic Acid ◽  
Coenzyme Q10 ◽  
Alpha Lipoic Acid ◽  
Experimental Diabetic Neuropathy

Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy

Life Sciences ◽  
2007 ◽  
Vol 80 (13) ◽  
pp. 1236-1244 ◽  
Author(s):  
Ashutosh Kumar ◽  
Ravinder K. Kaundal ◽  
Seethalakshmi Iyer ◽  
Shyam S. Sharma
Keyword(s):  
Oxidative Stress ◽  
Diabetic Neuropathy ◽  
Dna Fragmentation ◽  
Experimental Diabetic Neuropathy

The Roles of Oxidative Stress and Antioxidant Treatment in Experimental Diabetic Neuropathy

Diabetes ◽  
1997 ◽  
Vol 46 (Supplement_2) ◽  
pp. S38-S42 ◽  
Author(s):  
P. A. Low ◽  
K. K. Nickander ◽  
H. J. Tritschler
Keyword(s):  
Oxidative Stress ◽  
Diabetic Neuropathy ◽  
Antioxidant Treatment ◽  
Experimental Diabetic Neuropathy

scholarly journals Rosiglitazone Treatment Reduces Diabetic Neuropathy in Streptozotocin-Treated DBA/2J Mice

Endocrinology ◽  
2008 ◽  
Vol 149 (10) ◽  
pp. 4928-4937 ◽  
Author(s):  
Timothy D. Wiggin ◽  
Matthias Kretzler ◽  
Subramaniam Pennathur ◽  
Kelli A. Sullivan ◽  
Frank C. Brosius ◽  
...  
Keyword(s):  
Oxidative Stress ◽  
Gene Expression ◽  
Diabetic Neuropathy ◽  
Mouse Genome ◽  
Microarray Platform ◽  
Regulatory Elements ◽  
Common Complication ◽  
Insulin Sensitizer ◽  
Rosiglitazone Treatment ◽  
And Oxidative Stress

Diabetic neuropathy (DN) is a common complication of diabetes. Currently, there is no drug treatment to prevent or slow the development of DN. Rosiglitazone (Rosi) is a potent insulin sensitizer and may also slow the development of DN by a mechanism independent of its effect on hyperglycemia. A two by two design was used to test the effect of Rosi treatment on the development of DN. Streptozotocin-induced diabetic DBA/2J mice were treated with Rosi. DN and oxidative stress were quantified, and gene expression was profiled using the Affymetrix Mouse Genome 430 2.0 microarray platform. An informatics approach identified key regulatory elements activated by Rosi. Diabetic DBA/2J mice developed severe hyperglycemia, DN, and elevated oxidative stress. Rosi treatment did not affect hyperglycemia but did reduce oxidative stress and prevented the development of thermal hypoalgesia. Two novel transcription factor binding modules were identified that may control genes correlated to changes in DN after Rosi treatment: SP1F_ZBPF and EGRF_EGRF. These targets may be useful in designing drugs with the same efficacy as Rosi in treating DN but with fewer undesirable effects.

Sign in / Sign up

Export Citation Format

Share Document